Early brain amyloidosis in APP/PS1 mice with serum insulin-like growth factor-I deficiency.
The influence of insulin-like growth factor I (IGF-I) on the progression of Alzheimer's disease (AD) is discussed controversially. To help clarify the role of this circulating neurotrophic factor in brain amyloidosis, the major pathological trait in AD, we analyzed plaque formation in a mouse model of AD transgenic for human APP and PS1 mutations with reduced serum IGF-I levels (LIDAD mice). We found that brain amyloidosis in LIDAD mice appeared earlier than in AD mice, at 2 months of age, while attained comparable levels at 6 months. In parallel, early microgliosis was observed in LIDAD mice also at 2 months and remained exacerbated at 6 months. Collectively, these observations suggest a role of serum IGF-I in delaying early brain amyloidosis.
F. Hoffmann-LaRoche, CNS Pharma Research & Early Development, Basel, Switzerland.
R
R
Poirier
A M
AM
Fernandez
I
I
Torres-Aleman
F
F
Metzger
D017668:Age of Onset; D000375:Aging / Q000378:metabolism; D000544:Alzheimer Disease / Q000097:blood / Q000235:genetics / Q000378:metabolism; D016564:Amyloid beta-Protein Precursor / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D000686:Amyloidosis / Q000097:blood / Q000378:metabolism*; D000818:Animals; D001921:Brain / Q000378:metabolism* / Q000473:pathology*; D005260:Female; D005911:Gliosis / Q000097:blood / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000032:analysis / Q000172:deficiency*; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009154:Mutation; D053764:Presenilin-1 / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D013997:Time Factors
D016564:Amyloid beta-Protein Precursor; D053764:Presenilin-1; D007334:Insulin-Like Growth Factor I